You searched for "macular oedema"
Long-term treatment for diabetic macular oedema
2 April 2025
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
The authors set out to characterise anti-VEGF treatment patterns and long-term outcomes in patients with diabetic macular oedema. A retrospective analysis of over 190 thousand patients on the Intelligent Research in Sight registry was performed. Of these, 1236 eyes have...
Bromfenac versus betamethasone in diabetic macular oedema
31 October 2023
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
|
Diabetic macular edema, betamethasone, bromfenac, central subfield thickness, intraocular pressure
This is a randomised, prospective, single-centre trial in patients diagnosed with diabetic macular oedema (DMO) with central subfield thickness (CST) of 250-500µm, who refused anti-VEGF treatment. Nineteen eyes of 19 patients were randomised to bromfenac (BF) or betamethasone (BM) drops,...
Outcomes of treat & extend ranibizumab in diabetic macular oedema
1 October 2021
| Ed Rule
|
EYE - Vitreo-Retinal
|
Diabetic macular edema, Outcome predictor, Ranibizumab, Spectral-domain optical coherence tomography, Treat and extend
This study retrospectively evaluated 118 eyes of 87 patients who received ranibizumab in a treat and extend regimen for diabetic macular oedema (DMO). Data were collected for patients under follow-up for 24 months. After 24 months, patients gained a mean...
Steroid treatment for pseudophakic cystoid macular oedema
1 October 2021
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
|
Cystoid macular edema, intravitreal steroids, triamcinolone
The authors present a retrospective comparison of 45 eyes of 41 patients treated with 2mg intravitreal triamcinolone (IVT group) and 50 eyes of 42 patients treated with 40mg sub-Tenons triamcinolone (STT group) for pseudophakic cystoid macular oedema (CMO). The visual...
DRIL after macular oedema treatment in BRVO
1 June 2019
| Sofia Rokerya
|
EYE - Vitreo-Retinal
The authors report the analysis of a single-site, retrospective, cross-sectional study to evaluate the association between disorganisation of the retinal inner layers (DRIL) and visual acuity (VA) after anti-VEGF treatment for macular oedema (MO) due to branch retinal vein occlusion...
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema
1 April 2015
| Jonathan CP Roos
|
EYE - Vitreo-Retinal
Macular oedema (MO) is a leading cause of visual impairment in patients with diabetic retinopathy. Whilst laser photocoagulation therapy has been the proven treatment for decades, studies over the last five years have also established a role for anti-VEGF agents...
Avastin vs. Volon A for diabetic macular oedema
1 June 2014
| Nana Theodorou
|
EYE - Vitreo-Retinal
This prospective randomised interventional clinical trial compared 30 diabetic patients with macular oedema treated with either intravitreal injections of bevacizumab (Avastin) or triamcinolone (Volon A). One group initially received three injections of 2.5 mg Avastin in monthly intervals whilst the...
Macular oedema after cataract surgery in diabetic patients
1 December 2013
| Lorraine North
|
EYE - Vitreo-Retinal
The authors describe a multi-centre prospective observational study of 293 participants that underwent cataract surgery who all had diabetic retinopathy without definite central-involved macular oedema. Forty-five clinical sites took part throughout the United States. Patients were eligible if there was...
Intravitreal dexamethasone implant for diabetic macular oedema
The authors report on the three-year outcomes of the Ozurdex Dexamethasone (DEX) intravitreal implant multi-centre trial for the treatment of diabetic macular oedema (DME). Patients with DME (best-corrected vision of 20/50 to 20/200 and central retinal thickness of ≥300µm) were...OCT biomarkers in asymmetric anti-VEGF response in bilateral diabetic macular oedema
1 December 2021
| Su Young
|
EYE - Vitreo-Retinal
|
Diabetic macular edema, aflibercept, optical coherence tomography, predictive, ranibizumab
This study aimed to identify optical coherence tomography (OCT) biomarkers for predicting response to anti-VEGF treatment in diabetic macular oedema (DMO). Bilateral DMO patients with asymmetric response to a loading dose of anti-VEGF (ranibizumab / aflibercept) treatment were retrospectively studied....
Steroid implants in the treatment of post-epiretinal membrane peel macular oedema
1 February 2018
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
This is a retrospective review of 39 eyes of 37 patients treated with Ozurdex® (intravitreal dexamethasone implant) for persistent post-operative cystoid macular oedema (CMO) following vitrectomy and idiopathic epiretinal membrane (ERM) peeling. The 0.7mg implant was injected in each eye...
Inner nuclear layer of the retina showing increase in thickness in diabetic macular oedema
1 October 2015
| Bheemanagouda Patil
|
EYE - Vitreo-Retinal
Diabetic retinopathy is one of the leading causes of blindness in the developed world. With optical coherence tomography (OCT), it has become possible to image the retina in vivo and to measure retinal oedema by measuring retinal thickness (RT) with...